Sonnet BioTherapeutics Initiates Phase 1/2a Study for SON-1210
Sonnet BioTherapeutics Begins Clinical Research on SON-1210
Preclinical studies have shown SON-1210, a pioneering bifunctional IL-12/IL-15 fusion protein that binds to albumin, holds promise for immunotherapy in solid tumors.
An Innovative Immuno Oncology Consortium (IIOC), supported by the Sarcoma Oncology Center, is launching a Phase 1/2a study of SON-1210 aimed at treating pancreatic cancer, an area with critical unmet medical needs.
Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage enterprise focused on developing targeted immunotherapeutics, has officially announced the formation of a Master Clinical Collaboration Agreement with the Sarcoma Oncology Center. This agreement is pivotal to advancing the development of SON-1210 in conjunction with chemotherapy for metastatic pancreatic cancer.
Collaboration Goals and Strategic Importance
Pankaj Mohan, Ph.D., Founder and CEO of Sonnet, expressed enthusiasm about the collaboration, stating, “We are excited to partner with this highly regarded organization to push the boundaries of treatment for patients in dire need. Our focus will be on gathering critical information in this high-priority cancer area, which we believe will enhance our data portfolio and effectively manage our financial resources.”
Expert Insights on Pancreatic Cancer Treatment
Dr. Andrew Hendifar, a specialist in developing novel therapies for pancreatic cancer and neuroendocrine tumors, indicated the growing incidence of pancreatic cancer and limited advancements in treatments beyond conventional chemotherapies. He remarked, “Innovative immunotherapies such as SON-1210 represent a significant opportunity to elevate patient outcomes.”
Details of the Clinical Study
As outlined in the collaboration, IIOC, led by Dr. Sant Chawla at the Sarcoma Oncology Center, will design and implement an investigator-initiated Phase 1/2a study to test SON-1210 alongside various chemotherapy agents, including liposomal irinotecan, 5-fluorouracil/leucovorin, and oxaliplatin (known as NALIRIFOX). NALIRIFOX is recognized by the FDA for treating front-line and refractory metastatic pancreatic cancer, highlighting the study's significance.
Innovative Mechanisms and Benefits of SON-1210
Dr. Chawla emphasized the collaboration's importance, noting, “The preference of tumors for utilizing albumin means that albumin-bound treatments like SON-1210 may significantly enhance efficacy and safety due to their targeted action. This approach leverages our understanding of tumor biology where immunotherapies remain unapproved for pancreatic cancer.”
Dr. John Cini, Chief Scientific Officer and Co-Founder of Sonnet, elaborated on SON-1210's attributes. He highlighted its ability to enhance tumor targeting and retention by four to five-fold compared to traditional cytokines, addressing a critical unmet medical need in pancreatic cancer treatment.
Preclinical Safety and Efficacy Studies
Recently, the Company successfully carried out two IND-enabling toxicology studies of SON-1210 in non-human primates, yielding promising results with no significant toxicity. Observations include a temporary spike in interferon gamma (IFN?) post-administration, indicating the immunotherapeutic potential of the candidate.
Overview of SON-1210
SON-1210 represents a novel bifunctional immunotherapeutic candidate that combines IL-12 and IL-15 with an albumin-binding domain. The designed mechanism aims to deliver these cytokines effectively in tumor settings, thereby stimulating a robust immune response.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is an oncology-centric biotechnology firm dedicated to innovating biological drugs via its proprietary FHAB platform. This technology uses a human antibody fragment to transport therapeutic agents, ensuring targeted delivery to tumor tissues.
Frequently Asked Questions
1. What is SON-1210, and how does it work?
SON-1210 is a bifunctional immunotherapeutic drug that combines interleukins IL-12 and IL-15, designed to enhance immune responses in treating various cancers, particularly pancreatic cancer.
2. What is the significance of the study on SON-1210?
The study aims to investigate the efficacy of SON-1210 in combination with chemotherapy, addressing a significant gap in treatment options for patients with metastatic pancreatic cancer.
3. Who is conducting the clinical study of SON-1210?
The clinical study is spearheaded by the Innovative Immuno Oncology Consortium, led by Dr. Sant Chawla at the Sarcoma Oncology Center.
4. What are the potential benefits of using SON-1210?
SON-1210 could improve treatment outcomes for pancreatic cancer patients by leveraging its unique mechanism that enhances cytokine targeting and reduces toxicity compared to traditional therapies.
5. How does Sonnet BioTherapeutics approach drug development?
Sonnet BioTherapeutics employs its proprietary FHAB platform to innovate biologic drugs, focusing on improving their therapeutic efficacy and safety profiles through targeted delivery mechanisms.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/